Low back pain is a major health issue and one main cause to this condition is believed to be intervertebral disc (IVD) degeneration. Stem cell therapy for degenerated discs using mesenchymal stromal cells (MSCs) has been suggested. The aim of the study was to investigate the presence and distribution pattern of autologous MSCs transplanted into degenerated IVDs in patients and explanted posttransplantation. IVD tissues from four patients (41, 45, 47, and 47 years of age) participating in a clinical feasibility study on MSC transplantation to degenerative discs were investigated. Three patients decided to undergo fusion surgery at time points 8 months and one patient at 28 months posttransplantation. Pretransplantation, MSCs from bone marrow aspirate were isolated by centrifugation in FICOLL® test tubes and cultured (passage 1). Before transplantation, MSCs were labeled with 1 mg/mL iron sucrose (Venofer®) and 1 × 106 MSCs were transplanted into degenerated IVDs. At the time point of surgery, IVD tissues were collected. IVD tissue samples were fixated, embedded in paraffin, and sections prepared. IVD samples were stained with Prussian Blue, by which iron deposits are visualized and examined (light microscopy). Immunohistochemistry (IHC), including SOX9 (sex determining region Y box 9), Coll2A1 (collagen 2A1), and cell viability (TUNEL) were performed. Cells positive for iron deposits were observed in IVD tissues (3/4 patients). The cells/iron deposits were observed in clusters and/or as solitary cells in regions in IVD tissue samples [regions of interest (ROIs)]. By IHC, SOX9- and Coll2A1-positive cells were detected in the same regions as the detected cells/iron deposits. A few nonviable cells were detected by TUNEL assay in ROIs. Results demonstrated that MSCs, labeled with iron sucrose, transplanted into degenerated IVDs were detectable 8 months posttransplantation. The detected cellular activity indicates that MSCs have differentiated into chondrocyte-like cells and that the injected MSCs and/or their progeny have survived since the cells were found in large cluster and as solitary cells which were distributed at different parts of the IVD.
Get full access to this article
View all access options for this article.
References
1.
MaetzelA and LiL. (2002). The economic burden of low back pain: a review of studies published between 1996 and 2001. Best Pract Res Clin Rheumatol, 16:23–30.
2.
RisbudMV, AlbertTJ, GuttapalliA, VresilovicEJ, HillibrandAS, VaccaroAR and ShapiroIM. (2004). Differentiation of mesenchymal stem cells towards a nucleus pulposus-like phenotype in vitro: implications for cell-based transplantation therapy. Spine (Phila Pa 1976), 29:2627–2632.
3.
UrbanJP and RobertsS. (2003). Degeneration of the intervertebral disc. Arthritis Res Ther, 5:120–130.
4.
HenrikssonHB, SvanvikT, JonssonM, HagmanM, HornM, LindahlA and BrisbyH. (2009). Transplantation of human mesenchymal stems cells into intervertebral discs in a xenogeneic porcine model. Spine (Phila Pa 1976), 34:141–148.
5.
SakaiD, MochidaJ, YamamotoY, NomuraT, OkumaM, NishimuraK, NakaiT, AndoK and HottaT. (2003). Transplantation of mesenchymal stem cells embedded in Atelocollagen gel to the intervertebral disc: a potential therapeutic model for disc degeneration. Biomaterials, 24:3531–3541.
6.
Silva-CorreiaJ, CorreiaSI, OliveiraJM and ReisRL. (2013). Tissue engineering strategies applied in the regeneration of the human intervertebral disk. Biotechnol Adv, 31:1514–1531.
7.
KumarH, HaDH, LeeEJ, ParkJH, ShimJH, AhnTK, KimKT, RopperAE, SohnS, et al. (2017). Safety and tolerability of intradiscal implantation of combined autologous adipose-derived mesenchymal stem cells and hyaluronic acid in patients with chronic discogenic low back pain: 1-year follow-up of a phase I study. Stem Cell Res Ther, 8:262.
8.
NoriegaDC, ArduraF, Hernandez-RamajoR, Martin-FerreroMA, Sanchez-LiteI, ToribioB, AlbercaM, GarciaV, MoraledaJM, SanchezA and Garcia-SanchoJ. (2017). Intervertebral disc repair by allogeneic mesenchymal bone marrow cells: a randomized controlled trial. Transplantation, 101:1945–1951.
9.
MochidaJ, SakaiD, NakamuraY, WatanabeT, YamamotoY and KatoS. (2015). Intervertebral disc repair with activated nucleus pulposus cell transplantation: a three-year, prospective clinical study of its safety. Eur Cell Mater, 29:202–212; discussion 212.
10.
PettineKA, MurphyMB, SuzukiRK and SandTT. (2015). Percutaneous injection of autologous bone marrow concentrate cells significantly reduces lumbar discogenic pain through 12 months. Stem Cells, 33:146–156.
11.
OrozcoL, SolerR, MoreraC, AlbercaM, SanchezA and Garcia-SanchoJ. (2011). Intervertebral disc repair by autologous mesenchymal bone marrow cells: a pilot study. Transplantation, 92:822–828.
12.
HorwitzEM, GordonPL, KooWK, MarxJC, NeelMD, McNallRY, MuulL and HofmannT. (2002). Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone. Proc Natl Acad Sci U S A, 99:8932–8937.
13.
EapenM, KurtzbergJ, ZhangMJ, HatterselyG, FeiM, MendizabalA, ChanKW, De OliveiraS, SchultzKR, et al. (2017). Umbilical cord blood transplantation in children with acute leukemia: impact of conditioning on transplantation outcomes. Biol Blood Marrow Transplant, 23:1714–1721.
14.
ScrenciM, MurgiE, TamburiniA, PecciMR, BallatoreG, CusannoA, ValleV, LucianiP, CoronaF and GirelliG. (2015). Family directed umbilical cord blood banking for acute leukemia: usage rate in hematopoietic stem cell transplantation. Stem Cell Rev, 11:275–279.
15.
VanderA, ShermanJ, LucianoD, ed. (1987). Human Physiology. The Mechanisms of Body Function. Mc Graw-Hill. Inc., Singapore.
16.
KoschM, BahnerU, BettgerH, MatzkiesF, TeschnerM and SchaeferRM. (2001). A randomized, controlled parallel-group trial on efficacy and safety of iron sucrose (Venofer) vs iron gluconate (Ferrlecit) in haemodialysis patients treated with rHuEpo. Nephrol Dial Transplant, 16:1239–1244.
17.
LawenA and LaneDJ. (2013). Mammalian iron homeostasis in health and disease: uptake, storage, transport, and molecular mechanisms of action. Antioxid Redox Signal, 18:2473–2507.
18.
PrusE and FibachE. (2008). Flow cytometry measurement of the labile iron pool in human hematopoietic cells. Cytometry A, 73:22–27.
19.
WimpennyI, MarkidesH and El HajAJ. (2012). Orthopaedic applications of nanoparticle-based stem cell therapies. Stem Cell Res Ther, 3:13.
20.
GrootendorstDJ, JoseJ, FratilaRM, VisscherM, VeldersAH, Ten HakenB, Van LeeuwenTG, SteenbergenW, ManoharS and RuersTJ. (2013). Evaluation of superparamagnetic iron oxide nanoparticles (Endorem(R)) as a photoacoustic contrast agent for intra-operative nodal staging. Contrast Media Mol Imaging, 8:83–91.
21.
SvanvikT, HenrikssonHB, KarlssonC, HagmanM, LindahlA and BrisbyH. (2010). Human disk cells from degenerated disks and mesenchymal stem cells in co-culture result in increased matrix production. Cells Tissues Organs, 191:2–11.
22.
LiuW and FrankJA. (2009). Detection and quantification of magnetically labeled cells by cellular MRI. Eur J Radiol, 70:258–264.
23.
El HajAJ, GlossopJR, SuraHS, LeesMR, HuB, WolbankS, van GriensvenM, RedlH and DobsonJ. (2015). An in vitro model of mesenchymal stem cell targeting using magnetic particle labelling. J Tissue Eng Regen Med, 9:724–733.
24.
HandleyC, GoldschlagerT, OehmeD, GhoshP and JenkinG. (2015). Mesenchymal stem cell tracking in the intervertebral disc. World J Stem Cells, 7:65–74.
25.
QiY, FengG, HuangZ and YanW. (2012). The application of super paramagnetic iron oxide-labeled mesenchymal stem cells in cell-based therapy. Mol Biol Rep, 40:2733–2740.
26.
MarkidesH, KehoeO, MorrisRH and El HajAJ. (2013). Whole body tracking of superparamagnetic iron oxide nanoparticle-labelled cells—a rheumatoid arthritis mouse model. Stem Cell Res Ther, 4:126.
27.
SinghH, ReedJ, NobleS, CangianoJL and Van WyckDB. (2006). Effect of intravenous iron sucrose in peritoneal dialysis patients who receive erythropoiesis-stimulating agents for anemia: a randomized, controlled trial. Clin J Am Soc Nephrol, 1:475–482.
28.
WagnerW, SaffrichR and HoAD. (2008). The stromal activity of mesenchymal stromal cells. Transfus Med Hemother, 35:185–193.
29.
PapadimitriouN, ThorfveA, BrantsingC, JunevikK, BarantoA and Barreto HenrikssonH. (2014). Cell-viability and chondrogenic differentiation capability of human mesenchymal stem cells after iron-labelling with iron sucrose. Stem Cells Dev, 23:2568–2580.
30.
PapadimitriouN, LiS and Barreto HenrikssonH. (2015). Iron sucrose-labeled human mesenchymal stem cells: in vitro multilineage capability and in vivo traceability in a lapine xenotransplantation model. Stem Cells Dev, 24:2403–2412.
31.
MoldovanGL, PfanderB and JentschS. (2007). PCNA, the maestro of the replication fork. Cell, 129:665–679.
32.
Chimal-MonroyJ, Rodriguez-LeonJ, MonteroJA, GananY, MaciasD, MerinoR and HurleJM. (2003). Analysis of the molecular cascade responsible for mesodermal limb chondrogenesis: Sox genes and BMP signaling. Dev Biol, 257:292–301.
33.
CheahKS, StokerNG, GriffinJR, GrosveldFG and SolomonE. (1985). Identification and characterization of the human type II collagen gene (COL2A1). Proc Natl Acad Sci U S A, 82:2555–2559.
34.
HolnessCL and SimmonsDL. (1993). Molecular cloning of CD68, a human macrophage marker related to lysosomal glycoproteins. Blood, 81:1607–1613.
35.
BarotBS, ParejiyaPB, MehtaDM, ShelatPK and ShahGB. (2013). Physicochemical and structural characterization of iron-sucrose formulations: a comparative study. Pharm Dev Technol, 19:513–520.
36.
ScottJE, QuintarelliG and DellovoMC. (1964). The chemical and histochemical properties of Alcian Blue. I. The mechanism of Alcian Blue staining. Histochemie, 4:73–85.
37.
GoldsteinDJ and HorobinRW. (1974). Surface staining of cartilage by Alcian blue, with reference to the role of microscopic dye aggregates in histological staining. Histochem J, 6:175–184.
38.
HansenHA and WeinfeldA. (1959). Hemosiderin estimations and sideroblast counts in the differential diagnosis of iron deficiency and other anemias. Acta Med Scand, 165:333–356.
Le VisageC, KimSW, TatenoK, SieberAN, KostuikJP and LeongKW. (2006). Interaction of human mesenchymal stem cells with disc cells: changes in extracellular matrix biosynthesis. Spine (Phila Pa 1976), 31:2036–2042.
41.
VadalaG, StuderRK, SowaG, SpieziaF, IucuC, DenaroV, GilbertsonLG and KangJD. (2008). Coculture of bone marrow mesenchymal stem cells and nucleus pulposus cells modulate gene expression profile without cell fusion. Spine (Phila Pa 1976), 33:870–876.
42.
LuK, LiHY, YangK, WuJL, CaiXW, ZhouY and LiCQ. (2017). Exosomes as potential alternatives to stem cell therapy for intervertebral disc degeneration: in-vitro study on exosomes in interaction of nucleus pulposus cells and bone marrow mesenchymal stem cells. Stem Cell Res Ther, 8:108.
HenrikssonH, ThornemoM, KarlssonC, HaggO, JunevikK, LindahlA and BrisbyH. (2009). Identification of cell proliferation zones, progenitor cells and a potential stem cell niche in the intervertebral disc region: a study in four species. Spine (Phila Pa 1976), 34:2278–2287.
45.
WangH, ZhouY, ChuTW, LiCQ, WangJ, ZhangZF and HuangB. (2016). Distinguishing characteristics of stem cells derived from different anatomical regions of human degenerated intervertebral discs. Eur Spine J, 25:2691–2704.
46.
BrisbyH, PapadimitriouN, BrantsingC, BerghP, LindahlA and Barreto HenrikssonH. (2013). The presence of local mesenchymal progenitor cells in human degenerated intervertebral discs and possibilities to influence these in vitro: a descriptive study in humans. Stem Cells Dev, 22:804–814.
47.
RisbudMV, GuttapalliA, TsaiTT, LeeJY, DanielsonKG, VaccaroAR, AlbertTJ, GazitZ, GazitD and ShapiroIM. (2007). Evidence for skeletal progenitor cells in the degenerate human intervertebral disc. Spine (Phila Pa 1976), 32:2537–2544.
48.
BlancoJF, GracianiIF, Sanchez-GuijoFM, MuntionS, Hernandez-CampoP, SantamariaC, CarrancioS, BarbadoMV, CruzG, et al. (2010). Isolation and characterization of mesenchymal stromal cells from human degenerated nucleus pulposus: comparison with bone marrow mesenchymal stromal cells from the same subjects. Spine (Phila Pa 1976), 35:2259–2265.
49.
HuangYC, LeungVY, LuWW and LukKD. (2013). The effects of microenvironment in mesenchymal stem cell-based regeneration of intervertebral disc. Spine J, 13:352–362.
50.
SakaiD and AnderssonGB. (2015). Stem cell therapy for intervertebral disc regeneration: obstacles and solutions. Nat Rev Rheumatol, 11:243–256.
